Skip Nav Destination
Issues
1 January 2001
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Review
Clinical Trials
Simultaneous Immunomagnetic CD34+ Cell Selection and B-Cell Depletion in Peripheral Blood Progenitor Cell Samples of Patients Suffering from B-Cell Non-Hodgkin’s Lymphoma1
Michael Mohr; Fikri Dalmis; Eva Hilgenfeld; Elisabeth Oelmann; Michael Zühlsdorf; Karsten Kratz-Albers; Anette Nolte; Christiane Schmitmann; Derya Önaldi-Mohr; Uwe Cassens; Hubert Serve; Walter Sibrowski; Joachim Kienast; Wolfgang E. Berdel
A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities1
Francisco Bracho; Mark D. Krailo; Violet Shen; Sharon Bergeron; Virginia Davenport; Wen Liu-Mares; Bruce R. Blazar; Angela Panoskaltsis-Mortari; Carmella van de Ven; Rita Secola; Matthew M. Ames; Joel M. Reid; Gregory H. Reaman; Mitchell S. Cairo
Molecular Oncology, Markers, Clinical Correlates
Experimental Therapeutics, Preclinical Pharmacology
In Vitro Synergistic Interactions between the Cisplatin Analogue Nedaplatin and the DNA Topoisomerase I Inhibitor Irinotecan and the Mechanism of this Interaction1
Fumihiko Kanzawa; Fumiaki Koizumi; Yasuhiro Koh; Takashi Nakamura; Yasuaki Tatsumi; Hisao Fukumoto; Nagahiro Saijo; Takayuki Yoshioka; Kazuto Nishio
The Effects of KNK437, a Novel Inhibitor of Heat Shock Protein Synthesis, on the Acquisition of Thermotolerance in a Murine Transplantable Tumor in Vivo
Mototsugu Koishi; Shin’ichi Yokota; Tatsumasa Mae; Yasumasa Nishimura; Shuuichi Kanamori; Naotoshi Horii; Keiko Shibuya; Keisuke Sasai; Masahiro Hiraoka
Errata
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.